MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Wearing-off fluctuations"

  • 2017 International Congress

    Impact and communication of OFF periods in Parkinson disease

    T. Rastgardani, M. Armstrong, A. Gagliardi, C. Marras (Toronto, ON, Canada)

    Objective: To review existing literature on the impact and communication of OFF periods for patients with Parkinson disease (PwP) and carepartners. Background: Studies show associations…
  • 2017 International Congress

    Post-hoc analyses of the recommended starting dose for Rytary based on “off” time

    N. Modi, S. Khanna, S. Gupta (Hayward, CA, USA)

    Objective: To determine whether correcting for “off” time duration improves the selection of the final LD dose when converting to extended-release carbidopa-levodopa capsules (ER CD-LD,…
  • 2017 International Congress

    The Personal Kinetigraph Fluctuator Score Identifies Motor Fluctuations in Parkinson’s disease

    E. Tan, M. Tagliati, E. Hogg, M. Horne (Los Angeles, CA, USA)

    Objective: To evaluate the Personal Kinetigraph (PKG) fluctuator score (FS) in detecting motor fluctuations in Parkinson's disease (PD) patients. Background: Fluctuations of response to levodopa,…
  • 2016 International Congress

    Rotigotine transdermal patch in Chinese patients with advanced Parkinson’s disease: A randomized, double-blind study

    Z. Zhang, M. Asgharnejad, H. Xue, E. Surmann, L. Bauer (Beijing, People's Republic of China)

    Objective: A multicenter phase III study (SP1037; NCT01646255) to investigate the efficacy and safety of rotigotine in Chinese patients with advanced Parkinson's disease (PD). Background:…
  • 2016 International Congress

    Status of NPF-QII after six years: Updates to the dataset

    F. Cubillos, E.C. Nelson, T. Simuni, C. Marras, M. Rafferty, T. Davis, P. Schmidt (Miami, FL, USA)

    Objective: To describe the status and recent findings from the National Parkinson Foundation's Quality Improvement Initiative (NPF-QII), an 8,179 subject observational clinical study conducted at…
  • 2016 International Congress

    Wearable sensors and decision algorithms for advanced therapy referral in Parkinson’s disease

    D.A. Heldman, J.P. Giuffrida, E. Cubo (Cleveland, OH, USA)

    Objective: Pilot study to determine the impact of remote monitoring using objective, wearable sensors on the advanced therapy referral rate in patients with advanced Parkinson's…
  • 2016 International Congress

    Levodopa-carbidopa intestinal gel via PEG-J for advanced Parkinson’s disease- A single centre experience

    E. Pekkonen, J. Lyytinen, O. Lindström, L. Kylänpää, M. Udd (Helsinki, Finland)

    Objective: To investigate clinical outcome and possible complications of LCIG in patients with advanced PD in years 2006-2014 at Helsinki University Hospital. Background: Continuous levodopa-carbidopa…
  • 2016 International Congress

    Regional differences in the results of a phase 2b study of tozadenant in Parkinson’s disease patients with motor fluctuations

    C. Kenney, K. Kieburtz, W. Olanow, S. Bandak (San Francisco, CA, USA)

    Objective: To assess how the efficacy of tozadenant differed by region in a randomized, double-blind, placebo-controlled trial of Parkinson's disease patients with motor fluctuations. Background:…
  • 2016 International Congress

    Multiple system atrophy with motor fluctuations: A presynaptic disease variant?

    Y. Compta, S.C. Cerquera, N. Falgàs, E. Gelpí, V. Puente, A. Cámara, L. Planellas, M.J. Martí, F. Valldeoriola (Barcelona, Spain)

    Objective: To describe a case-series of Parkinsonian multiple system atrophy (MSAp) firstly diagnosed with Parkinson's disease (PD) due to clear-cut and severe l-dopa-induced motor fluctuations…
  • 2016 International Congress

    Duloxetine, a serotonin and norepinephrine reuptake inhibitor, reduces daily OFF time in Parkinson’s disease

    M. Tomiyama, Y. Funamizu, T. Kon, R. Haga, T. Ueno, H. Nishijima, A. Arai, C. Suzuki, J.I. Nunomura, M. Baba (Aomori, Japan)

    Objective: To evaluate efficacy of duloxetine on motor symptoms in Parkinson's disease (PD) patients with wearing-off in an open label trial. Background: Duloxetine, a serotonin…
  • « Previous Page
  • 1
  • …
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley